Annual CFO
-$361.82 M
-$69.06 M-23.59%
31 December 2023
Summary:
Iovance Biotherapeutics annual cash flow from operations is currently -$361.82 million, with the most recent change of -$69.06 million (-23.59%) on 31 December 2023. During the last 3 years, it has fallen by -$156.69 million (-76.38%). IOVA annual CFO is now -2512538.89% below its all-time high of -$14.40 thousand, reached on 31 December 2009.IOVA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$58.97 M
+$39.46 M+40.09%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly cash flow from operations is currently -$58.97 million, with the most recent change of +$39.46 million (+40.09%) on 30 September 2024. Over the past year, it has increased by +$25.11 million (+29.86%).IOVA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$363.65 M
+$25.11 M+6.46%
30 September 2024
Summary:
Iovance Biotherapeutics TTM cash flow from operations is currently -$363.65 million, with the most recent change of +$25.11 million (+6.46%) on 30 September 2024. Over the past year, it has dropped by -$8.13 million (-2.29%). IOVA TTM CFO is now -2525254.17% below its all-time high of -$14.40 thousand, reached on 31 December 2009.IOVA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -23.6% | +29.9% | -2.3% |
| 3 y3 years | -76.4% | -2.2% | -53.6% |
| 5 y5 years | -257.4% | -39.8% | -166.2% |
IOVA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -76.4% | at low | -9.5% | +51.8% | -59.5% | +6.5% |
| 5 y | 5 years | -257.4% | at low | -61.0% | +51.8% | -166.2% | +6.5% |
| alltime | all time | <-9999.0% | at low | <-9999.0% | +51.8% | <-9999.0% | +6.5% |
Iovance Biotherapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$58.97 M(-40.1%) | -$363.65 M(-6.5%) |
| June 2024 | - | -$98.43 M(-19.5%) | -$388.76 M(+1.2%) |
| Mar 2024 | - | -$122.28 M(+45.6%) | -$384.28 M(+6.2%) |
| Dec 2023 | -$361.82 M(+23.6%) | -$83.97 M(-0.1%) | -$361.82 M(+1.8%) |
| Sept 2023 | - | -$84.08 M(-10.5%) | -$355.52 M(+6.1%) |
| June 2023 | - | -$93.95 M(-5.9%) | -$335.09 M(+5.1%) |
| Mar 2023 | - | -$99.81 M(+28.5%) | -$318.77 M(+8.9%) |
| Dec 2022 | -$292.76 M(+28.4%) | -$77.67 M(+22.0%) | -$292.76 M(+8.9%) |
| Sept 2022 | - | -$63.65 M(-18.0%) | -$268.94 M(+2.3%) |
| June 2022 | - | -$77.64 M(+5.2%) | -$262.98 M(+9.9%) |
| Mar 2022 | - | -$73.80 M(+37.1%) | -$239.35 M(+5.0%) |
| Dec 2021 | -$227.94 M(+11.1%) | -$53.85 M(-6.7%) | -$227.94 M(-3.7%) |
| Sept 2021 | - | -$57.69 M(+6.8%) | -$236.78 M(+7.8%) |
| June 2021 | - | -$54.01 M(-13.4%) | -$219.61 M(+8.6%) |
| Mar 2021 | - | -$62.39 M(-0.5%) | -$202.23 M(-1.4%) |
| Dec 2020 | -$205.13 M(+29.1%) | -$62.69 M(+54.7%) | -$205.13 M(+4.5%) |
| Sept 2020 | - | -$40.52 M(+10.6%) | -$196.26 M(-0.8%) |
| June 2020 | - | -$36.63 M(-43.9%) | -$197.93 M(+1.5%) |
| Mar 2020 | - | -$65.29 M(+21.3%) | -$195.09 M(+22.8%) |
| Dec 2019 | -$158.89 M(+56.9%) | -$53.82 M(+27.6%) | -$158.89 M(+16.3%) |
| Sept 2019 | - | -$42.18 M(+24.8%) | -$136.62 M(+11.6%) |
| June 2019 | - | -$33.80 M(+16.2%) | -$122.36 M(+8.8%) |
| Mar 2019 | - | -$29.09 M(-7.8%) | -$112.49 M(+11.1%) |
| Dec 2018 | -$101.25 M(+28.6%) | -$31.55 M(+13.0%) | -$101.25 M(+11.7%) |
| Sept 2018 | - | -$27.93 M(+16.7%) | -$90.66 M(+7.7%) |
| June 2018 | - | -$23.92 M(+34.0%) | -$84.18 M(+8.3%) |
| Mar 2018 | - | -$17.85 M(-14.9%) | -$77.75 M(-1.2%) |
| Dec 2017 | -$78.71 M(+140.9%) | -$20.96 M(-2.2%) | -$78.71 M(+12.6%) |
| Sept 2017 | - | -$21.45 M(+22.6%) | -$69.90 M(+15.2%) |
| June 2017 | - | -$17.50 M(-7.0%) | -$60.67 M(+29.3%) |
| Mar 2017 | - | -$18.80 M(+54.6%) | -$46.92 M(+43.6%) |
| Dec 2016 | -$32.67 M | -$12.16 M(-0.4%) | -$32.67 M(+20.6%) |
| Sept 2016 | - | -$12.21 M(+225.7%) | -$27.09 M(+44.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$3.75 M(-17.7%) | -$18.72 M(-3.9%) |
| Mar 2016 | - | -$4.55 M(-30.8%) | -$19.47 M(+5.9%) |
| Dec 2015 | -$18.38 M(+112.9%) | -$6.58 M(+71.3%) | -$18.38 M(+21.6%) |
| Sept 2015 | - | -$3.84 M(-14.6%) | -$15.12 M(+16.3%) |
| June 2015 | - | -$4.50 M(+30.1%) | -$13.00 M(+32.3%) |
| Mar 2015 | - | -$3.46 M(+4.3%) | -$9.82 M(+13.8%) |
| Dec 2014 | -$8.63 M(+135.8%) | -$3.31 M(+91.8%) | -$8.63 M(+14.0%) |
| Sept 2014 | - | -$1.73 M(+30.7%) | -$7.57 M(+20.8%) |
| June 2014 | - | -$1.32 M(-41.7%) | -$6.27 M(+11.4%) |
| Mar 2014 | - | -$2.27 M(+0.7%) | -$5.63 M(+53.7%) |
| Dec 2013 | -$3.66 M(+63.3%) | -$2.25 M(+427.3%) | -$3.66 M(+159.8%) |
| Sept 2013 | - | -$427.10 K(-37.4%) | -$1.41 M(+11.6%) |
| June 2013 | - | -$681.90 K(+127.3%) | -$1.26 M(-29.1%) |
| Mar 2013 | - | -$300.00 K(<-9900.0%) | -$1.78 M(-20.5%) |
| Dec 2012 | -$2.24 M(-63.8%) | $0.00(-100.0%) | -$2.24 M(-54.7%) |
| Sept 2012 | - | -$280.70 K(-76.6%) | -$4.95 M(-21.7%) |
| June 2012 | - | -$1.20 M(+57.9%) | -$6.32 M(-1.0%) |
| Mar 2012 | - | -$760.20 K(-71.9%) | -$6.38 M(+3.2%) |
| Dec 2011 | -$6.19 M(+897.0%) | -$2.71 M(+64.3%) | -$6.19 M(+60.8%) |
| Sept 2011 | - | -$1.65 M(+30.3%) | -$3.85 M(+66.4%) |
| June 2011 | - | -$1.27 M(+124.2%) | -$2.31 M(+104.7%) |
| Mar 2011 | - | -$564.50 K(+52.7%) | -$1.13 M(+82.0%) |
| Dec 2010 | -$620.80 K(+4211.1%) | -$369.60 K(+226.2%) | -$620.80 K(+141.1%) |
| Sept 2010 | - | -$113.30 K(+37.7%) | -$257.50 K(+75.5%) |
| June 2010 | - | -$82.30 K(+48.0%) | -$146.70 K(+119.6%) |
| Mar 2010 | - | -$55.60 K(+782.5%) | -$66.80 K(+363.9%) |
| Dec 2009 | -$14.40 K(-75.9%) | -$6300.00(+152.0%) | -$14.40 K(-41.0%) |
| Sept 2009 | - | -$2500.00(+4.2%) | -$24.40 K(+6.6%) |
| June 2009 | - | -$2400.00(-25.0%) | -$22.90 K(-34.6%) |
| Mar 2009 | - | -$3200.00(-80.4%) | -$35.00 K(-41.5%) |
| Dec 2008 | -$59.80 K | -$16.30 K(+1530.0%) | -$59.80 K(+37.5%) |
| Sept 2008 | - | -$1000.00(-93.1%) | -$43.50 K(+2.4%) |
| June 2008 | - | -$14.50 K(-48.2%) | -$42.50 K(+51.8%) |
| Mar 2008 | - | -$28.00 K | -$28.00 K |
FAQ
- What is Iovance Biotherapeutics annual cash flow from operations?
- What is the all time high annual CFO for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual CFO year-on-year change?
- What is Iovance Biotherapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly CFO year-on-year change?
- What is Iovance Biotherapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics TTM CFO year-on-year change?
What is Iovance Biotherapeutics annual cash flow from operations?
The current annual CFO of IOVA is -$361.82 M
What is the all time high annual CFO for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual cash flow from operations is -$14.40 K
What is Iovance Biotherapeutics annual CFO year-on-year change?
Over the past year, IOVA annual cash flow from operations has changed by -$69.06 M (-23.59%)
What is Iovance Biotherapeutics quarterly cash flow from operations?
The current quarterly CFO of IOVA is -$58.97 M
What is the all time high quarterly CFO for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly cash flow from operations is $0.00
What is Iovance Biotherapeutics quarterly CFO year-on-year change?
Over the past year, IOVA quarterly cash flow from operations has changed by +$25.11 M (+29.86%)
What is Iovance Biotherapeutics TTM cash flow from operations?
The current TTM CFO of IOVA is -$363.65 M
What is the all time high TTM CFO for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high TTM cash flow from operations is -$14.40 K
What is Iovance Biotherapeutics TTM CFO year-on-year change?
Over the past year, IOVA TTM cash flow from operations has changed by -$8.13 M (-2.29%)